R&D Strategy

AKLRD’s focus is in inflammatory diseases, particularly those related to dysregulation of the innate immune system.

AKLRD identifies secondary metabolites of plant origin with proven efficacy & safety, and which are capable of being synthesized. These synthetic metabolites then undergo standard pharmaceutical clinical development.

AKLRD’s innovative approach greatly increases the chances of success, while reducing the probability of unexpected side effects.

AKLRD has identified two molecules which act synergistically and have been combined to create AKL4 [APPA], a patented investigational oral medicine showing great promise in the treatment of inflammatory conditions including osteoarthritis, a highly prevalent and devastating disease with limited treatment options and no cure.

Having recently completed a Phase I study, a Phase II study due to start Q3 2020.